NYSE: AIM - AIM ImmunoTech Inc.

Yield per half year: -63.36%
Dividend yield: 0.00%
Sector: Healthcare

Share chart AIM ImmunoTech Inc.

Extended chart Simple chart
Financial Markets by TradingView

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

more details
It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1996-07-12
ISIN US00901B1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://aimimmuno.com
Цена ао 0.1297
Change price per day: 0% (0.0949)
Change price per week: 0% (0.0949)
Change price per month: -20.92% (0.12)
Change price per 3 month: -49.95% (0.1896)
Change price per half year: -63.36% (0.259)
Change price per year: -83.11% (0.562)
Change price per 3 year: -87.35% (0.75)
Change price per 5 year: -90.88% (1.04)
Change price per year to date: -51.33% (0.195)
All parameters

Underestimation

Title Value Grade
P/S 69.2 1
P/BV 5.06 3
P/E 0 0
EV/EBITDA 0 0
Total: 3.13

Efficiency

Title Value Grade
ROA, % -159.57 0
ROE, % 0 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 21.43 4
Yield Ebitda, % 207.7 10
Yield EPS, % -70.2 0
Total: 5.6
More

Institutions Volume Share, %
Vanguard Group Inc 1988704 3.99
Blackrock Inc. 707806 1.42
Geode Capital Management, LLC 351657 0.7
Renaissance Technologies, LLC 202008 0.4
State Street Corporation 173103 0.35
Verition Fund Management, LLC 162000 0.32
Bridgeway Capital Management, Inc. 108900 0.22
Northern Trust Corporation 85566 0.17
Morgan Stanley 77318 0.15
Seacrest Wealth Management, LLC 37063 0.07



Head Job title Payment Year of birth
Mr. Thomas K. Equels Esq., J.D., M.S. Executive Vice Chairman, CEO & President 953.19k 1953 (72 years)
Mr. Robert Dickey IV, M.B.A. Chief Financial Officer 64.48k 1956 (69 years)
Mr. Peter W. Rodino III, Esq., J.D. COO, Executive Director of Governmental Relations, General Counsel & Secretary 484.94k 1951 (74 years)
Ann Marie E. Coverly Director of Administration & Human Resources and Deputy Investor Relations Coordinator N/A
Dr. Christopher McAleer Ph.D. Scientific Officer N/A
Dr. Ralph Christopher Cavalli Ph.D. Vice President of QC & Manufacturing 234.79k 1958 (67 years)

Address: United States, Ocala. FL, 2117 SW Highway 484 - open in Google maps, open in Yandex maps
Website: https://aimimmuno.com